- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03360422
ANCHORS Study: UH2 Project (ANCHORS)
Advancing New Computer-based Health Outcomes Regarding Sexual Behavior(ANCHORS) Study: UH2 Project
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Web-survey:
- Male sex
- Ages 18-30
- Ability to read and write English
- 1 or more instances of sexual activity with another man in the past 3 months
- HIV Negative
Focus group:
- 18-35
- All other inclusion criteria will be the same as the web survey
Usability phase:
- 5 or more drinks in a day in the past month
- Past-month intercourse with another man without a condom
- Willingness to try PrEP, but have never tried it before
Exclusion Criteria:
Web Screen:
- No subject may have lifetime use of PrEP
Focus group:
- A current undergraduate or graduate student at any level in one of the 3 departments that make up the College of Health and Human Performance (HHP) at the University of Florida (UF), where Dr. Leeman's faculty appointment is.
- Do not want to engage in open discussion regarding substance use or sexual activity/orientation in a group setting. It will be possible for participants to contribute to focus group discussions without providing detailed information about their own substance use or sexual activity, however focus group participants must have a degree of openness to discussing these topics with others. These groups will take place with 6-7 other people and some people may be made uncomfortable by the discussions that may take place with regard to participants' drinking, substance use or sexual behavior.
- Not willing to be recorded via an electronic recording device
Usability phase:
- No subject may have lifetime use of PrEP
- Those who do not wish to provide a reliable phone number will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Survey group
Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
|
Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey.
Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
|
|
Active Comparator: Focus Group
30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
|
Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey.
Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
After informed consent, participants will complete the web-based intervention component in development.
Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
|
|
Active Comparator: Usability Study
10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
|
Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey.
Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantity of Alcohol Consumption
Time Frame: Retrospective self-report over the past month
|
Determine levels of alcohol consumption in study population
|
Retrospective self-report over the past month
|
|
High-risk Sexual Behavior: Condomless Sex
Time Frame: Retrospective self-report from past month on web survey
|
Past month frequency of condomless sex
|
Retrospective self-report from past month on web survey
|
|
Study Participant Opinions on Acceptability of Intervention Content
Time Frame: Up to one month
|
Participants in the usability study will report on the acceptability of the interactive voice response (IVR) system and the personalized feedback produced based on their IVR responses. On a modified System Usability Scale, participants in the usability study will report on the acceptability (i.e., perceived value, liking) of the interactive voice response (IVR) system and the personalized feedback produced based on their IVR responses. Items were rated on a 1-7 scale with higher scores indicating greater usability. The acceptability subscale is made up of 5 items. The score reported below is the mean of these five items. |
Up to one month
|
|
Study Participant Opinions on Usability of Intervention Content
Time Frame: Up to 1 month
|
On a modified System Usability Scale, participants in the usability study will report on the usability of the interactive voice response (IVR) system and the personalized feedback produced based on their IVR responses.
Items were rated on a 1-7 scale with higher scores indicating greater usability.
The usability subscale is made up of 4 items.
The score reported below is the mean of these four items.
|
Up to 1 month
|
|
High-risk Sexual Behavior: Sexual Activity During/After Alcohol Use
Time Frame: Past month on a self-report survey
|
Past month frequency of alcohol use before or during oral, anal and/or vaginal sex
|
Past month on a self-report survey
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Leeman, PhD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IRB201701367 N
- UH2AA026214-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Federal University of São PauloGilead SciencesCompleted
-
Fundación HuéspedViiV HealthcareNot yet recruitingHIV-1-infectionArgentina, Brazil
-
Fundación HuéspedMSD Pharmaceuticals LLC; Fundacion IDEAANot yet recruiting
-
Henan Genuine Biotech Co., Ltd.Recruiting
-
University of North Carolina, Chapel HillNot yet recruiting
-
Craig Cohen, MD, MPHNational Institute of Allergy and Infectious Diseases (NIAID); Duke University and other collaboratorsRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting
-
BioNTech SERecruitingHIV -1 InfectionGermany, United States
-
TaiMed Biologics Inc.Active, not recruitingHIV -1 InfectionUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)Not yet recruitingHIV -1 Infection | Methamphetamine UseUnited States
Clinical Trials on Survey
-
Johns Hopkins Bloomberg School of Public HealthPontificia Universidad JaverianaCompletedNoncommunicable Diseases | Surveys and QuestionnairesColombia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Weill Medical College of Cornell UniversityBoston Children's Hospital; Brigham and Women's Hospital; The Commonwealth FundCompletedPediatric ALLUnited States
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Université de Cergy PontoiseCompleted
-
Sarasota Memorial Health Care SystemEnrolling by invitation
-
Ohio State UniversityWithdrawnMedicare Part DUnited States
-
Johns Hopkins Bloomberg School of Public HealthIfakara Health InstituteCompletedNoncommunicable Diseases | Surveys and QuestionnairesTanzania
-
Memorial Sloan Kettering Cancer CenterCompletedInpatients With Limited English ProficiencyUnited States
-
Lawson Health Research InstituteCompletedEvaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation ParticipationMyocardial Infarction | Unstable Angina | Coronary Angioplasty | Coronary Artery Bypass SurgeryCanada